Original Article
Brief Report
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
N Engl J Med 2003; 348:1342-1347April 3, 2003
- Article
Until recently, vancomycin was the only uniformly effective treatment for staphylococcal infections. In 1997, the first clinical isolate of Staphylococcus aureus with reduced susceptibility to vancomycin was reported,1 and as of June 2002, eight confirmed infections with such strains had been reported in patients in the United States.2-6 The minimal inhibitory concentrations (MICs) of vancomycin reported for these isolates are in the intermediate range (8 to 16 μg per milliliter) according to interpretive criteria defined by the National Committee for Clinical Laboratory Standards.7
In June 2002, a clinical isolate of vancomycin-resistant S. aureus (VRSA) (MIC, >32 μg per milliliter) was identified.8 In this report, we describe our investigation of this infection, describe the mechanism of resistance, and discuss the clinical significance and public health implications of this finding.
Case Report
The patient, a 40-year-old woman who lived in Michigan, had hypertension, diabetes mellitus, peripheral vascular disease, and chronic renal failure, which had necessitated hemodialysis since August 1999. The patient had recurrent foot ulcers due to diabetic neuropathy and localized infections of the right lower leg. In March 2001, she underwent amputation of the right fifth metatarsal, which was gangrenous. Cultures of the amputation wound site revealed heavy growth of oxacillin-susceptible S. aureus (MIC, ≤0.25 μg per milliliter). Two months later, she was successfully treated for an infected fissure and associated foot cellulitis; cultures of the fissure showed minimal growth of vancomycin-susceptible methicillin-resistant S. aureus and vancoymcin-susceptible Enterococcus faecalis.
From January to March 2002, recurrent infections of the foot ulcers were treated empirically with systemic antimicrobial agents, including vancomycin, gentamicin, ampicillin–sulbactam, piperacillin–tazobactam, levofloxacin, clindamycin, cefazolin, trimethoprim–sulfamethoxazole, tobramycin, and metronidazole (Figure 1Figure 1
Clinical Events and Antimicrobial Therapy in a Patient with Vancomycin-Resistant S. aureus Infection from January through June 2002.). The patient's condition required amputation of the right first metatarsal in February 2002 and the right fourth metatarsal in April 2002. During this time, the patient was changing her own dressings daily and using a loose-fitting foot covering. As of July 2002, the foot ulcerations had persisted.During the hospitalization for the amputation in April 2002, methicillin-resistant S. aureus bacteremia developed, as did an abscess associated with an arteriovenous graft for dialysis access (Gore-Tex). The patient received vancomycin for 3 weeks and rifampin for 10 days. After removal of the graft, access for hemodialysis was maintained with the use of three sequentially placed, temporary, nontunneled dialysis catheters until June 14, at which time a newly placed graft became functional. The first temporary catheter was removed on May 23 because of a suspected exit-site infection (growth on the catheter tip of >15 colonies of methicillin-resistant S. aureus, with sterile blood cultures). The patient was treated with one dose of vancomycin. The second catheter was placed on May 23 and then removed electively on June 6, and a third temporary catheter was placed. In sum, during the six months before the identification of VRSA, the patient had received vancomycin for a total of six and a half weeks.
On June 14, the third temporary catheter was removed because of a suspected exit-site infection, and one dose of vancomycin and one dose of gentamicin were given. Cultures of exudates from the catheter exit site and from the catheter tip subsequently grew VRSA (MIC, ≥32 μg per milliliter), identified simultaneously by two local clinical microbiology laboratories that processed two separate specimens. The catheter-tip specimen also grew vancomycin-resistant E. faecalis (MIC, ≥32 μg per milliliter). The identification and susceptibility of the S. aureus isolates were confirmed by the Michigan Department of Community Health and by the Centers for Disease Control and Prevention (CDC). One week after the catheter was removed, the exit site appeared to have healed. However, a culture of specimens from two plantar ulcers, obtained to evaluate a possible soft-tissue infection, also contained VRSA and vancomycin-resistant E. faecalis, as well as Klebsiella oxytoca and Candida albicans.
Cultures of swab specimens obtained from other sites (the nares, axilla, and umbilicus and the catheter exit site) on June 21 and June 28 were negative for VRSA. However, cultures of swabs from the nares and umbilicus grew vancomycin-susceptible, methicillin-resistant S. aureus. In addition, a culture of a perirectal-swab specimen grew vancomycin-resistant E. faecalis but no S. aureus.
On July 2, the patient underwent surgical débridement of the foot ulcers on an outpatient basis. She completed a 14-day postoperative course of trimethoprim–sulfamethoxazole and metronidazole. The ulcers were evaluated twice per week, with débridement if necessary, application of gentian violet, and application of contact casts. Each of the three foot ulcers was cultured weekly for VRSA, which was recovered on July 16 and August 20. By December 2002, the patient's ulcers had healed.
Methods
To document any cross-transmission of VRSA to other persons, we performed a carriage survey of the patient's known contacts during the period from April 25 through July 2, 2002 — that is, the last date before the isolation of VRSA that vancomycin-susceptible S. aureus was isolated from multiple sites until the first date that all cultured specimens grew no VRSA. To assess the possibility of previous transmission, we identified social and health care–associated contacts, including all family members, close friends, concurrent health care providers, and patients cared for on the same hospital ward or in the same clinic office on the days when the patient infected with VRSA was present. Specimens from as many contacts as possible were collected from the anterior nares, any catheter sites, and any open wounds or skin lesions.
To identify any ongoing transmission during the investigation, we prospectively monitored all health care personnel involved in the care of the VRSA-infected patient by culturing specimens from their anterior nares weekly and examining the cultures for VRSA. We also reviewed infection-control policies, interviewed health care personnel, and observed infection-control practices at the facilities where the patient was receiving care.
VRSA isolates recovered from the patient's catheter tip and catheter exit site were initially identified at two local hospital laboratories with the use of MIC testing methods (Dade MicroScan). Species identification was carried out by standard biochemical methods.9
Genomic staphylococcal and enterococcal DNA, isolated by the silica-gel–membrane method (Qiagen DNeasy), was used as a template for the polymerase chain reaction to detect the presence of mecA, 10 vanA, vanB, vanC, 11 and vanD.12 DNA sequences were determined with an automated sequencer (ABI377, Applied Biosystems).13 Antimicrobial-susceptibility testing was performed by the broth-microdilution method.7 Pulsed-field gel electrophoresis was performed on SmaI macrorestriction fragments of DNA from the isolates of VRSA and methicillin-resistant S. aureus from the patient, her family members, and other dialysis-center patients.14,15 The Dice coefficients (representing the percent similarities) of gel-electrophoresis restriction profiles were then compared (BioNumerics analysis software, Applied Maths).
During the carriage survey, specimens from the patient's contacts were collected with dry, sterile swabs (Culturette, Becton Dickinson). The swabs were inoculated onto mannitol salt agar. After a 48-hour incubation at 35°C, all presumptive S. aureus colonies were isolated on blood-agar plates containing 5 percent sheep's blood for further analysis. Identification of S. aureus was confirmed by Gram's staining, catalase testing, latex-agglutination testing (Staphaurex, Murex), and tube coagulase testing, if indicated. Finally, to screen for vancomycin resistance, all S. aureus isolates were inoculated onto brain–heart infusion agar containing 6 μg of vancomycin per milliliter and incubated at 35°C for 24 hours.
Results
Epidemiologic Studies
During the period of potential transmissibility, the patient had received care at one free-standing dialysis center (dialysis center A) and at one physician's outpatient office and had been admitted to a single hospital on three occasions. The patient lived alone but frequently received nine family members and one close friend into her home. During this period, she was not employed.
Contacts were identified at each of these three health care facilities. Two of the contacts at dialysis center A had switched to another center, dialysis center B. One business establishment, a nail salon, was identified as having been frequently visited by the patient and thus as carrying the potential for transmission of VRSA to its employees. All contacts from these facilities who were available for interview agreed to have specimens taken from the anterior nares for culture. We obtained specimens from 371 of the 547 identified contacts. Of the 371 cultured specimens, 110 (30 percent) were positive for S. aureus, including 28 (8 percent of the 371 cultures) that were positive for methicillin-resistant S. aureus (Table 1Table 1
Survey of S. aureus Carriage among Contacts of a Patient Infected with Vancomycin-Resistant S. aureus.). No carriage of VRSA was identified. In the prospective evaluations of staff from dialysis center A and staff from the podiatry center caring for the patient, no carriage of VRSA was identified.Each of these health care settings had written infection-control policies. The hospital used broad universal precautions similar to the standard precautions recommended by the CDC (i.e., use of gloves if any contact with body fluids is anticipated, use of gowns for contact in which soiling of clothes is anticipated, and use of masks if splashing is anticipated).16 Similar measures were used in the physician's office. The dialysis centers followed infection-control guidelines consistent with the CDC's recommendations for preventing the transmission of infections among patients undergoing long-term hemodialysis.17 Observed practices were consistent with the written policies.
Laboratory Studies
Species identification of the VRSA isolate from the catheter exit site was confirmed by biochemical tests. Polymerase-chain-reaction assays for vancomycin-resistant loci revealed only vanA. The DNA sequence of the vanA gene from the VRSA isolate was identical to the vanA sequence of transposon Tn1546 18 and to the vanA sequence from the patient's E. faecalis isolate.
In analyses of the VRSA, the MIC of vancomycin was 1024 μg per milliliter by broth microdilution and greater than 256 μg per milliliter by the agar gradient-diffusion method (Etest, AB Biodisk). On disk-diffusion testing, the VRSA had no zone of inhibition, although an 18-mm zone of reduced growth was perceptible around the disk. The isolate was susceptible to chloramphenicol, linezolid, minocycline, quinupristin–dalfopristin, tetracycline, and trimethoprim–sulfamethoxazole (Table 2Table 2
Antimicrobial-Susceptibility Profile of the Vancomycin-Resistant Strain of S. aureus.). The characteristics and susceptibilities of the initial isolates of VRSA from the patient were identical to those of subsequent isolates.Pulsed-field gel electrophoresis of SmaI macrorestriction fragments revealed that the banding patterns of the initial VRSA isolate were indistinguishable from those of the subsequent VRSA isolated from the patient's foot ulcers; indistinguishable from the vancomycin-susceptible, methicillin-resistant S. aureus isolated from the patient's nares; and indistinguishable from a methicillin-resistant S. aureus isolated from the patient's close friend. Other methicillin-resistant S. aureus strains, isolated from a family member and from 13 patients at dialysis center A, were less than 85 percent similar to the patient's initial VRSA isolate according to Dice coefficient analysis.
Discussion
This report describes a patient infected with fully vancomycin-resistant S. aureus that contained the vanA vancomycin-resistance gene. Although the acquired vancomycin-resistance genes vanA, vanB, vanD, vanE, vanF, and vanG have been reported in vancomycin-resistant enterococci, these genes have not previously been identified in any clinical isolates of S. aureus. However, conjugative transfer of the vanA gene from enterococci to S. aureus has been demonstrated in vitro.19 We suspect the vanA detected in the current patient's VRSA isolate probably originated in vancomycin-resistant E. faecalis, which was also isolated from the patient. Although the DNA sequence of the vanA gene in these two strains was identical, additional studies are needed to confirm this hypothesis.
An extensive search for VRSA in all the patient's contacts was undertaken, and no VRSA was identified. However, a close friend of the patient did carry a vancomycin-susceptible, methicillin-resistant strain of S. aureus that was indistinguishable from the VRSA on pulsed-field gel electrophoresis. This finding underscores the importance of extending efforts to prevent and reduce the spread of methicillin-resistant S. aureus beyond inpatient facilities.
This VRSA isolate was susceptible in vitro to several antimicrobial agents, including quinupristin–dalfopristin and linezolid, which were recently approved by the Food and Drug Administration and have activity against other glycopeptide-resistant, gram-positive microorganisms. The availability of these agents, developed since the first report of S. aureus with reduced susceptibility to vancomycin (vancomycin-intermediate S. aureus), 1 provides several options for treating this patient. However, most of the MICs reported for these agents are just one dilution below the susceptibility break point.
There are several similarities between this VRSA infection and the previously reported infections with vancomycin-intermediate S. aureus.1-6 First, the patient infected with VRSA had been exposed for several weeks to vancomycin and had had recurrent infections with methicillin-resistant S. aureus during the preceding months, as did the patients with vancomycin-intermediate S. aureus. Second, the patient infected with VRSA had underlying illnesses, including diabetes mellitus and chronic renal failure, similar to those affecting most of the previously described patients.4 Although the isolates from these patients tended to be susceptible to chloramphenicol, linezolid, quinupristin–dalfopristin, and trimethoprim–sulfamethoxazole, the VRSA isolate was highly resistant to vancomycin (MIC, 1024 μg per milliliter), whereas the vancomycin-intermediate S. aureus isolates were only moderately resistant to it (MIC, 8 μg per milliliter).4
Although recommended measures to control the spread of methicillin-resistant S. aureus and vancomycin-resistant enterococci in hospitals have been promoted for several years,20,21 surveillance data suggest that the existence of these recommendations has not appreciably slowed the increasing rate of infection or colonization with either of these organisms in the United States. The reasons for this lack of effect are unclear and under debate. In some institutions, the recommended measures may be ineffective or poorly followed or implemented.
Preventing the emergence of multidrug-resistant organisms will require a comprehensive, systematic approach that integrates the health care and public health systems. We need to encourage and facilitate adherence to recommended prevention and control guidelines, conduct active surveillance to detect the emergence of these organisms, and ensure vigorous antibiotic stewardship by health care providers. All isolates of S. aureus with presumptive vancomycin resistance should be saved, their resistance (or susceptibility) status confirmed by MIC-testing methods, and the test results reported through state and local health departments to the Division of Healthcare Quality Promotion of the National Center for Infectious Diseases of the CDC (mailstop E-68, Atlanta, GA 30333; telephone number, 800-893-0485; e-mail, search@cdc.gov).
The use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the Department of Health and Human Services.
Dr. Brown reports having received research support from Merck and Daiichi and speaker's fees from Dade Behring.
We are indebted to the following people for their valuable contributions to the work of the Vancomycin-Resistant Staphylococcus aureus Investigative Team: A. Whitney, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta; L. Chiarello, L. Sehulster, J. Tokars, M. Pearson, J. Jernigan, M. Kuehnert, and S. Solomon, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention; J. Collins, B. Carlson, J. Montgomery, S. Hutto, G. Palumbo, and D. Ganoczy, Michigan Department of Community Health, Detroit; S. Migdahl, G. Heathscott, and D. Reid, Wayne State University School of Medicine and Detroit Medical Center, Detroit; and staff members of hemodialysis centers A and B, Detroit.
Source Information
From the Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office (S.C.), and the Division of Healthcare Quality Promotion, National Center for Infectious Diseases (J.C.H., F.C.T., D.C., S.K.F.), Centers for Disease Control and Prevention, Atlanta; the Bureau of Epidemiology (D.M.S., M.L.B.) and the Bureau of Laboratories (F.P.D., S.S., J.T.R.), Michigan Department of Community Health, Lansing; Lakeview Podiatry Associates, Dearborn, Mich. (G.R.P.); and the Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center University Laboratories, Detroit (W.J.B.).
Address reprint requests to Dr. Fridkin at the Centers for Disease Control and Prevention, 1600 Clifton Rd., Mailstop A-35, Atlanta, GA 30333, or at sfridkin@cdc.gov.
Other members of the investigative team are listed in the Appendix.
Appendix
In addition to the authors, the following people participated in the Vancomycin-Resistant Staphylococcus aureus Investigative Team: Michigan Department of Community Health, Lansing, Mich. — G. Stoltman and P. Somsel; Detroit Medical Center, Detroit — T. Lundstrom, E. Flanagan, and W. Hafeez; Oakwood Healthcare System, Dearborn, Mich. — J. Mitchell; hemodialysis center A, Detroit — R. Johnson; and Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Diseases Control and Prevention, Atlanta — S. McAllister, L. McDougal, M. Kellum, H. Holmes, J. Chaitram, P. Raney, G. Fosheim, L. Weigel, N. Clark, and M. Arduino.
- References
References
1
Reduced susceptibility of Staphylococcus aureus to vancomycin -- Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-626
Medline2
Smith TL ,Pearson ML ,Wilcox KR , et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501
Full Text | Web of Science | Medline3
Rotun SS ,McMath V ,Schoonmaker DJ , et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-149
CrossRef | Web of Science | Medline4
Fridkin SK . Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001;32:108-115
CrossRef | Web of Science | Medline5
Staphylococcus aureus with reduced susceptibility to vancomycin -- Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000;48:1165-1167
Medline6
Hageman JC ,Pegues DA ,Jepson C , et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001;7:1023-1025
CrossRef | Web of Science | Medline7
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Vol. 17. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 2000.
8
Staphylococcus aureus resistant to vancomycin -- United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567
Medline9
Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999:264-82.
10
Vannuffel P ,Gigi J ,Ezzedine H , et al. Specific detection of methicillin-resistant Staphylococcus species by multiplex PCR. J Clin Microbiol 1995;33:2864-2867
Web of Science | Medline11
Clark NC ,Cooksey RC ,Hill BC ,Swenson JM ,Tenover FC . Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993;37:2311-2317
Web of Science | Medline12
Ostrowsky BE ,Clark NC ,Thauvin-Eliopoulos C , et al. A cluster of VanD vancomycin-resistant Enterococcus faecium: molecular characterization and clinical epidemiology. J Infect Dis 1999;180:1177-1185
CrossRef | Web of Science | Medline13
Weigel LM ,Anderson GJ ,Facklam RR ,Tenover FC . Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:3517-3523
CrossRef | Web of Science | Medline14
Bannerman TL ,Hancock GA ,Tenover FC ,Miller JM . Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol 1995;33:551-555
Web of Science | Medline15
Maslow JN, Slutsky AM, Arbeit RD. Application of pulsed-field gel electrophoresis to molecular epidemiology. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic molecular microbiology: principles and applications. Washington, D.C.: American Society for Microbiology, 1993:563-72.
16
Garner JS . Guideline for isolation precautions in hospitals. I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996;24:24-31
CrossRef | Web of Science | Medline17
Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep 2001;50:1-43
Medline18
Arthur M ,Molinas C ,Depardieu F ,Courvalin P . Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993;175:117-127
Web of Science | Medline19
Noble WC ,Virani Z ,Cree RG . Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-198
CrossRef | Web of Science | Medline20
Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44:1-13
Medline21
Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:626-8, 635
Medline
- Citing Articles (263)
Citing Articles
1
Meenakashi Gupta, Marlene L. Durand, Lucia Sobrin. (2012) Vancomycin Resistance in Ocular Infections. International Ophthalmology Clinics 51:4, 167-181
CrossRef2
Zeina A. Kanafani, G. Ralph Corey. (2012) Tedizolid (TR-701) : a new oxazolidinone with enhanced potency. Expert Opinion on Investigational Drugs1-8
CrossRef3
H.-J. Tang, C.-C. Chen, K.-C. Cheng, H.-S. Toh, B.-A. Su, S.-R. Chiang, W.-C. Ko, Y.-C. Chuang. (2012) In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. Journal of Antimicrobial Chemotherapy
CrossRef4
Emma R. Scaletti, Sylvia R. Luckner, Kurt L. Krause. (2012) Structural features and kinetic characterization of alanine racemase from Staphylococcus aureus (Mu50). Acta Crystallographica Section D Biological Crystallography 68:1, 82-92
CrossRef5
Wanwipa Vongsangnak, Luís Filipe Figueiredo, Jochen Förster, Tilmann Weber, Jette Thykaer, Evi Stegmann, Wolfgang Wohlleben, Jens Nielsen. (2012) Genome-scale metabolic representation of Amycolatopsis balhimycina. Biotechnology and Bioengineeringn/a-n/a
CrossRef6
P. Moreillon, A. Bizzini, M. Giddey, J. Vouillamoz, J. M. Entenza. (2011) Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest. Journal of Antimicrobial Chemotherapy
CrossRef7
Pleun J. van Duijn, Mirjam J.D. Dautzenberg, Evelien A.N. Oostdijk. (2011) Recent trends in antibiotic resistance in European ICUs. Current Opinion in Critical Care 17:6, 658-665
CrossRef8
S.A. Rebiahi, D.E. Abdelouahid, M. Rahmoun, S. Abdelali, H. Azzaoui. (2011) Emergence of vancomycin-resistant Staphylococcus aureus identified in the Tlemcen university hospital (North-West Algeria). Médecine et Maladies Infectieuses
CrossRef9
Takashi Suzuki. (2011) A New Target for Staphylococcus aureus Associated With Keratitis. Cornea 30, S34-S40
CrossRef10
Jie Chen, Thomas C Cesario, Peter M Rentzepis. (2011) Research Spotlight: Accurate delivery of chemicals and intense light on infected areas only for targeted therapy inside the body. Therapeutic Delivery 2:10, 1241-1245
CrossRef11
D. R. Cameron, B. P. Howden, A. Y. Peleg. (2011) The Interface Between Antibiotic Resistance and Virulence in Staphylococcus aureus and Its Impact Upon Clinical Outcomes. Clinical Infectious Diseases 53:6, 576-582
CrossRef12
Yoichi Hiraki, Yasuhiro Tsuji, Mikako Hiraike, Nobuhiro Misumi, Kana Matsumoto, Kunihiko Morita, Hidetoshi Kamimura, Yoshiharu Karube. (2011) Correlation between serum linezolid concentration and the development of thrombocytopenia. Scandinavian Journal of Infectious Diseases1-5
CrossRef13
Jack Brown, Kristen A. Brown, Alan Forrest. (2011) Outcomes and Costs Associated With a History of Vancomycin Exposure in Patients With MRSA-Related Complicated Bacteremia and Infective Endocarditis. Clinical Therapeutics
CrossRef14
Erin A. Christensen, Kim Joho, Karl R. Matthews. (2011) Secondary Transfer and Expression of vanA in Enterococcus faecium Derived from a Commensal Vancomycin-Susceptible Enterococcus faecium Multi-Component Food Isolate. Microbial Drug Resistance 17:3, 369-376
CrossRef15
Y. K. Yoon, S. E. Lee, J. Lee, H. J. Kim, J. Y. Kim, D. W. Park, J. W. Sohn, M. J. Kim. (2011) Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study. Journal of Antimicrobial Chemotherapy 66:8, 1831-1838
CrossRef16
A. Fischer, S.-J. Yang, A. S. Bayer, A. R. Vaezzadeh, S. Herzig, L. Stenz, M. Girard, G. Sakoulas, A. Scherl, M. R. Yeaman, R. A. Proctor, J. Schrenzel, P. Francois. (2011) Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. Journal of Antimicrobial Chemotherapy 66:8, 1696-1711
CrossRef17
J. An, G.Y. Zuo, X.Y. Hao, G.C. Wang, Z.S. Li. (2011) Antibacterial and synergy of a flavanonol rhamnoside with antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). Phytomedicine 18:11, 990-993
CrossRef18
Fei Sun, Lu Zhou, Bing-Chuan Zhao, Xin Deng, Hoonsik Cho, Chengqi Yi, Xing Jian, Chun-Xiao Song, Chi-Hao Luan, Taeok Bae, Zigang Li, Chuan He. (2011) Targeting MgrA-Mediated Virulence Regulation in Staphylococcus aureus. Chemistry & Biology 18:8, 1032-1041
CrossRef19
Hung-Jen Tang, Chi-Chung Chen, Wen-Chien Ko, Wen-Liang Yu, Shyh-Ren Chiang, Yin-Ching Chuang. (2011) In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2μg/mL (VA2-MRSA). International Journal of Antimicrobial Agents 38:1, 46-51
CrossRef20
Michael D. Nailor, Jack D. Sobel. (2011) Antibiotics for Gram-Positive Bacterial Infection: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Telavancin, and Ceftaroline. Medical Clinics of North America 95:4, 723-742
CrossRef21
E. Meyer, R. Ziegler, F. Mattner, F. Schwab, P. Gastmeier, M. Martin. (2011) Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae. Infection
CrossRef22
Mingzhu Jin, Zhaowei Gu, Zhigang Bian, Jing Yang, Zhiwei Cao, Xiaofeng Yu, Genyan Guo. (2011) Developing a mouse model of acute bacterial rhinosinusitis. European Archives of Oto-Rhino-Laryngology 268:6, 857-861
CrossRef23
Sandrine Henard, Vincent Gendrin, Loïc Simon, Nathalie Jouzeau, Nathalie Vernier, Jean-Michel Thiolet, Bruno Coignard, Christian Rabaud. (2011) Control of a regional outbreak of vanA glycopeptide-resistant Enterococcus faecium, Eastern France, 2004–2009. International Journal of Hygiene and Environmental Health 214:3, 265-270
CrossRef24
C. Surcouf, M. Fabre, V. Enouf, S. Cadé, C. Soler, C. Mac Nab, T. Samson, V. Foissaud. (2011) Portage d’entérocoques résistants aux glycopeptides : les techniques d’isolement et d’identification actuelles sont-elles suffisantes ?. Pathologie Biologie 59:3, 146-150
CrossRef25
Yoichi Hiraki, Yasuhiro Tsuji, Kana Matsumoto, Kunihiko Morita, Hidetoshi Kamimura, Yoshiharu Karube. (2011) Influence of Linezolid Clearance on the Induction of Thrombocytopenia and Reduction of Hemoglobin. The American Journal of the Medical Sciences1
CrossRef26
Mahir Kaya, Göksel Şimşek-Kaya, Nesrin Gürsan, Ekrem Kireççi, Ertunç Dayı, Betül Gündoğdu. (2011) Local treatment of chronic osteomyelitis with surgical debridement and tigecycline-impregnated calcium hydroxyapatite: an experimental study. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
CrossRef27
Fredrik Nederberg, Ying Zhang, Jeremy P. K. Tan, Kaijin Xu, Huaying Wang, Chuan Yang, Shujun Gao, Xin Dong Guo, Kazuki Fukushima, Lanjuan Li, James L. Hedrick, Yi-Yan Yang. (2011) Biodegradable nanostructures with selective lysis of microbial membranes. Nature Chemistry 3:5, 409-414
CrossRef28
Tyler G. St. Denis, Liyi Huang, Tianhong Dai, Michael R. Hamblin. (2011) Analysis of the Bacterial Heat Shock Response to Photodynamic Therapy-mediated Oxidative Stress. Photochemistry and Photobiology 87:3, 707-713
CrossRef29
Xin Zhang, Yu Liu, Yaping Gao, Jie Dong, Chunhua Mu, Qiang Lu, Ningsheng Shao, Guang Yang. (2011) Inhibiting platelets aggregation could aggravate the acute infection caused by Staphylococcus aureus. Platelets 22:3, 228-236
CrossRef30
Simona Niederhäusern, Moreno Bondi, Patrizia Messi, Ramona Iseppi, Carla Sabia, Giuliano Manicardi, Immacolata Anacarso. (2011) Vancomycin-resistance Transferability from VanA Enterococci to Staphylococcus aureus. Current Microbiology 62:5, 1363-1367
CrossRef31
Alice G. Cheng, Andrea C. DeDent, Olaf Schneewind, Dominique Missiakas. (2011) A play in four acts: Staphylococcus aureus abscess formation. Trends in Microbiology 19:5, 225-232
CrossRef32
Naresh Sunduru, Leena Gupta, Kuldeep Chauhan, Nripendra N. Mishra, Praveen K. Shukla, Prem M.S. Chauhan. (2011) Synthesis and antibacterial evaluation of novel 8-fluoro Norfloxacin derivatives as potential probes for methicillin and vancomycin-resistant Staphylococcus aureus. European Journal of Medicinal Chemistry 46:4, 1232-1244
CrossRef33
Stephen P. Hawser, Samuel K. Bouchillon, Daryl J. Hoban, Michael Dowzicky, Tim Babinchak. (2011) Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009. International Journal of Antimicrobial Agents 37:3, 219-224
CrossRef34
Andy Hesketh, Chris Hill, Jehan Mokhtar, Gabriela Novotna, Ngat Tran, Mervyn Bibb, Hee-Jeon Hong. (2011) Genome-wide dynamics of a bacterial response to antibiotics that target the cell envelope. BMC Genomics 12:1, 226
CrossRef35
Richard W. Gantt, Pauline Peltier-Pain, Jon S. Thorson. (2011) Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules. Natural Product Reports 28:11, 1811
CrossRef36
John S. Bradley, Christopher R. Cannavino, Deborah E. Franzon, Susan Duthie. 2011. Bacterial Infection, Antimicrobial Use, and Antibiotic-Resistant Organisms in the Pediatric Intensive Care Unit. , 1315-1323.
CrossRef37
Srdjan Jovetic, Yang Zhu, Giorgia Letizia Marcone, Flavia Marinelli, Johannes Tramper. (2010) β-Lactam and glycopeptide antibiotics: first and last line of defense?. Trends in Biotechnology 28:12, 596-604
CrossRef38
Steven L Barriere. (2010) ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiology 5:12, 1765-1773
CrossRef39
F. Brossier, S. Lefrançois, J. Paute, A. Gouot, J.-L. Golmard, P. Chaibi, E. Pautas, S. Berigaud, L. Drieux, V. Jarlier, A. Aubry. (2010) Decolonisation for early control of an outbreak of vancomycin-resistant Enterococcus faecium in a geriatric rehabilitation care facility. Journal of Hospital Infection 76:4, 368-369
CrossRef40
Tobias Welte, Mathias W. Pletz. (2010) Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. International Journal of Antimicrobial Agents 36:5, 391-400
CrossRef41
Subramanian Swaminathan, George J. Alangaden. (2010) Treatment of Resistant Enterococcal Urinary Tract Infections. Current Infectious Disease Reports 12:6, 455-464
CrossRef42
Christopher M. Bland, William H. Porr, Kepler A. Davis, Karon B. Mansell. (2010) Vancomycin MIC Susceptibility Testing of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Isolates: A Comparison Between Etest® and an Automated Testing Method. Southern Medical Journal 103:11, 1124-1128
CrossRef43
Evangelo Boumis, Giovanni Gesu, Francesco Menichetti, Marco Ranieri, Mauro Rinaldi, Fredy Suter, Emanuele Nicastri, Francesco N. Lauria, Giampiero Carosi, Mauro Moroni, Giuseppe Ippolito. (2010) Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis. International Journal of Infectious Diseases 14, S23-S38
CrossRef44
Ioanna Eleftheriadou, Nicholas Tentolouris, Vasiliki Argiana, Edward Jude, Andrew J. Boulton. (2010) Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections. Drugs 70:14, 1785-1797
CrossRef45
Duncan Chambers, Gillian Worthy, Lindsey Myers, Helen Weatherly, Rachel Elliott, Neil Hawkins, Mark Sculpher, Alison Eastwood. (2010) Glycopeptide vs. Non-Glycopeptide Antibiotics for Prophylaxis of Surgical Site Infections: A Systematic Review. Surgical Infections 11:5, 455-462
CrossRef46
R. Sykes. (2010) The 2009 Garrod Lecture: The evolution of antimicrobial resistance: a Darwinian perspective. Journal of Antimicrobial Chemotherapy 65:9, 1842-1852
CrossRef47
Karen K. Kinney. (2010) Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria. The American Journal of the Medical Sciences 340:3, 209-217
CrossRef48
Zsuzsanna Dombrádi, Z. Bihari, Katalin Illésné Horváth, Judit Szabó. (2010) Comparison of the VITEK 2 system with the E-test for the determination of glycopeptide susceptibility of <i>vanA</i> and <i>vanC</i> positive enterococci. Acta Microbiologica et Immunologica Hungarica 57:3, 157-163
CrossRef49
H. K. Kim, A. G. Cheng, H.-Y. Kim, D. M. Missiakas, O. Schneewind. (2010) Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. Journal of Experimental Medicine 207:9, 1863-1870
CrossRef50
Yumei GONG, Jun CHEN, Tao YANG, Zongzhen LI, Guoyou LI. (2010) Secondary Metabolites with Anti-Staphylococcus aureus Activity from Streptomyces hygroscopicus*. Chinese Journal of Appplied Environmental Biology 16:2, 261-263
CrossRef51
E. Goldberg, M. Paul, O. Talker, Z. Samra, M. Raskin, R. Hazzan, L. Leibovici, J. Bishara. (2010) Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy 65:8, 1779-1783
CrossRef52
Roberta Cortivo, Vincenzo Vindigni, Laura Iacobellis, Giovanni Abatangelo, Paolo Pinton, Barbara Zavan. (2010) Nanoscale particle therapies for wounds and ulcers. Nanomedicine 5:4, 641-656
CrossRef53
Daria Nicolosi, Marina Scalia, Vito M. Nicolosi, Rosario Pignatello. (2010) Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. International Journal of Antimicrobial Agents 35:6, 553-558
CrossRef54
K. Hegstad, T. Mikalsen, T. M. Coque, G. Werner, A. Sundsfjord. (2010) Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcus faecalis and Enterococcus faecium. Clinical Microbiology and Infection 16:6, 541-554
CrossRef55
G. Jacobsson, P. Colque-Navarro, E. Gustafsson, R. Andersson, R. Möllby. (2010) Antibody responses in patients with invasive Staphylococcus aureus infections. European Journal of Clinical Microbiology & Infectious Diseases 29:6, 715-725
CrossRef56
E. J. M. Verkade, C. J. M. M. Verhulst, X. W. Huijsdens, J. A. J. W. Kluytmans. (2010) In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains. European Journal of Clinical Microbiology & Infectious Diseases 29:5, 503-507
CrossRef57
C.-M. Ho, P.-R. Hsueh, C.-Y. Liu, S.-Y. Lee, T.-S. Chiueh, J.-M. Shyr, S.-M. Tsao, Y.-C. Chuang, J.-J. Yan, L.-S. Wang, J.-H. Wang, M.-W. Ho, N. Tien, J.-J. Lu. (2010) Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan—SMART program, 2003. European Journal of Clinical Microbiology & Infectious Diseases 29:4, 383-389
CrossRef58
Ian M. Gould. 2010. Antibacterial Therapy. .
CrossRef59
Subhankari Prasad Chakraborty, Sumanta Kumar Sahu, Santanu Kar Mahapatra, Susmita Santra, Manjusri Bal, Somenath Roy, Panchanan Pramanik. (2010) Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents. Nanotechnology 21:10, 105103
CrossRef60
Chuanguang Qin, Chunlan Xu, Ruijie Zhang, Weining Niu, Xiaoya Shang. (2010) On-resin cyclization and antimicrobial activity of Laterocidin and its analogues. Tetrahedron Letters 51:9, 1257-1261
CrossRef61
Rachel A. Elliott, Helen L. A. Weatherly, Neil S. Hawkins, Gillian Cranny, Duncan Chambers, Lindsey Myers, Alison Eastwood, Mark J. Sculpher. (2010) An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?. The European Journal of Health Economics 11:1, 57-66
CrossRef62
Choong-Hwan Cha, Hae Kyong An, Jeong Uk Kim. (2010) Detection of Vancomycin-resistant Enterococci using Multiplex Real-time PCR Assay and Melting Curve Analysis. The Korean Journal of Laboratory Medicine 30:2, 138
CrossRef63
Marco A. Ciufolini, David Lefranc. (2010) Micrococcin P1: Structure, biology and synthesis. Natural Product Reports 27:3, 330
CrossRef64
A. Sorlozano, J. Gutierrez, T. Martinez, M. E. Yuste, J. A. Perez-Lopez, A. Vindel, J. Guillen, T. Boquete. (2010) Detection of new mutations conferring resistance to linezolid in glycopeptide-intermediate susceptibility Staphylococcus hominis subspecies hominis circulating in an intensive care unit. European Journal of Clinical Microbiology & Infectious Diseases 29:1, 73-80
CrossRef65
Patrick M. Schlievert, Kristi L. Strandberg, Ying-Chi Lin, Marnie L. Peterson, Donald Y.M. Leung. (2010) Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. Journal of Allergy and Clinical Immunology 125:1, 39-49
CrossRef66
P. M. Hawkey. (2009) Low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus and how to test it. Clinical Microbiology and Infection 15, 2-9
CrossRef67
Michael D. Nailor, Jack D. Sobel. (2009) Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin. Infectious Disease Clinics of North America 23:4, 965-982
CrossRef68
Knut Ohlsen. (2009) Novel antibiotics for the treatment of Staphylococcus aureus. Expert Review of Clinical Pharmacology 2:6, 661-672
CrossRef69
Martin E Stryjewski, G Ralph Corey. (2009) New treatments for methicillin-resistant Staphylococcus aureus. Current Opinion in Critical Care 15:5, 403-412
CrossRef70
George M. Eliopoulos. (2009) Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. Journal of Infection 59, S17-S24
CrossRef71
Sandra Bliss Nelson. (2009) Management of diabetic foot infections in an era of increasing microbial resistance. Current Infectious Disease Reports 11:5, 375-382
CrossRef72
Lindsey M. Gottler, Ayyalusamy Ramamoorthy. (2009) Structure, membrane orientation, mechanism, and function of pexiganan — A highly potent antimicrobial peptide designed from magainin. Biochimica et Biophysica Acta (BBA) - Biomembranes 1788:8, 1680-1686
CrossRef73
Alessandra Agostinho, Garth James, Oussama Wazni, Mark Citron, Bruce D. Wilkoff. (2009) Inhibition of Staphylococcus aureus Biofilms by a Novel Antibacterial Envelope for Use with Implantable Cardiac Devices. Clinical and Translational Science 2:3, 193-198
CrossRef74
Vinai Chittezham Thomas, Yasuaki Hiromasa, Nathan Harms, Lance Thurlow, John Tomich, Lynn E. Hancock. (2009) A fratricidal mechanism is responsible for eDNA release and contributes to biofilm development of Enterococcus faecalis. Molecular Microbiology 72:4, 1022-1036
CrossRef75
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, . (2009) Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. Journal of Antimicrobial Chemotherapy 63:5, 849-861
CrossRef76
Matan J. Cohen, Amos Adler, Colin Block, Ilana Gross, Naomi Minster, Varda Roval, Rachel Tchakirov, Allon E. Moses, Shmuel Benenson. (2009) Acquisition of vancomycin-resistant enterococci in internal medicine wards. American Journal of Infection Control 37:2, 111-116
CrossRef77
Adam C. Schaffer, Jean C. Lee. (2009) Staphylococcal Vaccines and Immunotherapies. Infectious Disease Clinics of North America 23:1, 153-171
CrossRef78
Sang Hoon Han, Bum Sik Chin, Han Sung Lee, Su Jin Jeong, Hee Kyung Choi, Chang Ki Kim, Chang Oh Kim, Dongeun Yong, Jun Yong Choi, Young Goo Song, Kyungwon Lee, June Myung Kim. (2009) Recovery of Both Vancomycin‐Resistant Enterococci and Methicillin‐Resistant Staphylococcus aureus From Culture of a Single Clinical Specimen From Colonized or Infected Patients. Infection Control and Hospital Epidemiology 30:2, 130-138
CrossRef79
H. M. Heyman, A. A. Hussein, J. J. M. Meyer, N. Lall. (2009) Antibacterial activity of South African medicinal plants against methicillin resistant Staphylococcus aureus. Pharmaceutical Biology 47:1, 67-71
CrossRef80
Krzysztof Buczek, Mateusz Marć. (2009) Antybiotykooporność bakterii - przyczyny i skutki. Annales UMCS, Medicina Veterinaria 64:3, 1-8
CrossRef81
E. Chorianopoulos, F. Bea, H. A. Katus, N. Frey. (2009) The role of endothelial cell biology in endocarditis. Cell and Tissue Research 335:1, 153-163
CrossRef82
S. Chusri, S.P. Voravuthikunchai. (2009) Detailed studies on Quercus infectoria Olivier (nutgalls) as an alternative treatment for methicillin-resistant Staphylococcus aureus infections. Journal of Applied Microbiology 106:1, 89-96
CrossRef83
G. Ralph Corey, Martin E. Stryjewski, Richard J. Everts. (2009) Short-course therapy for bloodstream infections in immunocompetent adults. International Journal of Antimicrobial Agents 34, S47-S51
CrossRef84
Li Gu, Bin Cao, Yingmei Liu, Ping Guo, Shufan Song, Ran Li, Huaping Dai, Chen Wang. (2009) A new Tn1546 type of VanB phenotype–vanA genotype vancomycin-resistant Enterococcus faecium isolates in mainland China. Diagnostic Microbiology and Infectious Disease 63:1, 70-75
CrossRef85
John E. Mazuski. (2008) Vancomycin-Resistant Enterococcus : Risk Factors, Surveillance, Infections, and Treatment. Surgical Infections 9:6, 567-571
CrossRef86
Peter K Linden. (2008) Vancomycin resistance: are there better glycopeptides coming?. Expert Review of Anti-infective Therapy 6:6, 917-928
CrossRef87
Pramodini Kale-Pradhan, Leonard B Johnson. (2008) Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. Expert Review of Anti-infective Therapy 6:6, 909-915
CrossRef88
S. Jahagirdar, R. Patwardhan, P.K. Dhakephalkar. (2008) Curing plasmid-mediated vancomycin resistance in Staphylococcus aureus using herbal naphthoquinones. Journal of Hospital Infection 70:3, 289-291
CrossRef89
Yoshio Matsuda, Hidehito Kato, Erina Ono, Ken Kikuchi, Mitsue Muraoka, Koichiro Takagi, Ken'ichi Imanishi, Shun'ichi Itoh, Tatsuo Itoh, Tetsuya Ogawa, Kosaku Nitta, Sayaka Inokuchi, Toshifumi Hibi, Hiroaki Ohta, Takehiko Uchiyama. (2008) Diagnosis of toxic shock syndrome by two different systems; clinical criteria and monitoring of TSST-1-reactive T cells. Microbiology and Immunology 52:11, 513-521
CrossRef90
P. M. Hawkey. (2008) Pre-clinical experience with daptomycin. Journal of Antimicrobial Chemotherapy 62:Supplement 3, iii7-iii14
CrossRef91
Guido Werner, Birgit Strommenger, Wolfgang Witte. (2008) Acquired vancomycin resistance in clinically relevant pathogens. Future Microbiology 3:5, 547-562
CrossRef92
Luis Fernando Aranha Camargo. (2008) TREATMENT OF SEVERE INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS. Shock 30:Suppl 1, 67-69
CrossRef93
Cesar A Arias, Barbara E Murray. (2008) Emergence and management of drug-resistant enterococcal infections. Expert Review of Anti-infective Therapy 6:5, 637-655
CrossRef94
Elena Loza, María Isabel Morosini, Álvaro Pascual, Fe Tubau, Juan Alcalá, Josefina Liñares, José Ramón Hernández-Bello, Fernando Baquero, Evelio Perea, Rogelio Martín, Ronald N. Jones, Rafael Cantón. (2008) Actividad comparativa de daptomicina frente a microorganismos grampositivos: programa SENTRY España (2002-2006). Enfermedades Infecciosas y Microbiología Clínica 26:8, 489-494
CrossRef95
Wolfgang Witte, Christiane Cuny, Ingo Klare, Ulrich Nübel, Birgit Strommenger, Guido Werner. (2008) Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. International Journal of Medical Microbiology 298:5-6, 365-377
CrossRef96
Udo Reischl, Thomas Holzmann. (2008) Aktuelle Verfahren zum Nukleinsäure gestützten Direktnachweis von MRSA / Direct nucleic acid-based detection of MRSA in clinical specimens. LaboratoriumsMedizin 32:4, 253-265
CrossRef97
Udo Reischl, Thomas Holzmann. (2008) Direct nucleic acid-based detection of MRSA from clinical specimens 1. LaboratoriumsMedizin 32:4, ---
CrossRef98
Itzhak Brook. (2008) Clinical trials report. Current Infectious Disease Reports 10:3, 179-181
CrossRef99
Jesus Lopez-Alcalde, Lucieni O Conterno, Marta Mateos-Mazón, Marcela Guevara-Eslava, Francisco Job-Neto, Ivan Solà, Jesus Lopez-Alcalde. 2008. Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital setting.. .
CrossRef100
J. Chastre. (2008) Evolving problems with resistant pathogens. Clinical Microbiology and Infection 14:s3, 3-14
CrossRef101
C. Sabia, S. de Niederhäusern, E. Guerrieri, P. Messi, I. Anacarso, G. Manicardi, M. Bondi. (2008) Detection of bacteriocin production and virulence traits in vancomycin-resistant enterococci of different sources. Journal of Applied Microbiology 104:4, 970-979
CrossRef102
Marianna Ofner‐Agostini, B. Lynn Johnston, Andrew E. Simor, John Embil, Anne Matlow, Michael Mulvey, Debbie Ormiston, John Conly, . (2008) Vancomycin‐Resistant Enterococci in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1999‐2005 • . Infection Control and Hospital Epidemiology 29:3, 271-274
CrossRef103
D. M. Sievert, J. T. Rudrik, J. B. Patel, L. C. McDonald, M. J. Wilkins, J. C. Hageman. (2008) Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006. Clinical Infectious Diseases 46:5, 668-674
CrossRef104
F. C. Tenover. (2008) Vancomycin-Resistant Staphylococcus aureus: A Perfect but Geographically Limited Storm?. Clinical Infectious Diseases 46:5, 675-677
CrossRef105
P M Hawkey. (2008) Molecular epidemiology of clinically significant antibiotic resistance genes. British Journal of Pharmacology 153:S1, S406-S413
CrossRef106
R. N. Jones. (2008) Key considerations in the treatment of complicated staphylococcal infections. Clinical Microbiology and Infection 14, 3-9
CrossRef107
Donald P. Levine. (2008) Vancomycin: Understanding Its Past and Preserving Its Future. Southern Medical Journal 101:3, 284-291
CrossRef108
Dayang F. Basri ., Noraziah M. Zin ., Nur Salwani Bakar ., Faralisa Rahmat ., Mastura Mohtar .. (2008) Synergistic Effects of Phytochemicals and Oxacillin on Laboratory Passage-Derived Vancomycin-Intermediate Staphylococcus aureus Strain. Journal of Medical Sciences(Faisalabad) 8:2, 131-136
CrossRef109
James S Lewis, Michael W Ellis. (2008) Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management. Current Opinion in Internal Medicine 7:1, 65-70
CrossRef110
Ki Ho Hong, Jeong Su Park, Eui-Chong Kim. (2008) Two Cases of Vancomycin-intermediate Staphylococcus aureus Isolated from Joint Tissue or Wound. The Korean Journal of Laboratory Medicine 28:6, 444
CrossRef111
Nao Otsuka, Mei-Hua Liu, Sumiko Shiota, Wakano Ogawa, Teruo Kuroda, Tsutomu Hatano, Tomofusa Tsuchiya. (2008) Anti-methicillin Resistant Staphylococcus aureus (MRSA) Compounds Isolated from Laurus nobilis. Biological & Pharmaceutical Bulletin 31:9, 1794-1797
CrossRef112
Carlos Pigrau, José Barberán. (2008) Infecciones de piel y partes blandas por grampositivos multirresistentes. Enfermedades Infecciosas y Microbiología Clínica 26, 21-30
CrossRef113
David Hooper. 2007. Target Modification as a Mechanism of Antimicrobial Resistance. , 133-167.
CrossRef114
Peter K. Linden. 2007. Enterococci: Resistance Update and Treatment Options. , 89-110.
CrossRef115
Jane D. Siegel, Emily Rhinehart, Marguerite Jackson, Linda Chiarello. (2007) 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. American Journal of Infection Control 35:10, S65-S164
CrossRef116
Jane D. Siegel, Emily Rhinehart, Marguerite Jackson, Linda Chiarello. (2007) Management of multidrug-resistant organisms in health care settings, 2006. American Journal of Infection Control 35:10, S165-S193
CrossRef117
J. R. Lentino, M. Narita, V. L. Yu. (2007) New antimicrobial agents as therapy for resistant gram-positive cocci. European Journal of Clinical Microbiology & Infectious Diseases 27:1, 3-15
CrossRef118
Michael A. Marques, Diane M. Citron, Clay C. Wang. (2007) Development of Tyrocidine A analogues with improved antibacterial activity. Bioorganic & Medicinal Chemistry 15:21, 6667-6677
CrossRef119
Ryoichi Shimomura, Yutaka Tsutsumi. (2007) Histochemical identification of Methicillin-resistant Staphylococcus aureus: contribution to preventing nosocomial infection. Seminars in Diagnostic Pathology 24:4, 217-226
CrossRef120
Peter C. Appelbaum. (2007) Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents 30:5, 398-408
CrossRef121
R. Menges, G. Muth, W. Wohlleben, E. Stegmann. (2007) The ABC transporter Tba of Amycolatopsis balhimycina is required for efficient export of the glycopeptide antibiotic balhimycin. Applied Microbiology and Biotechnology 77:1, 125-134
CrossRef122
Evelina Tacconelli, Maria A Cataldo. (2007) Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opinion on Pharmacotherapy 8:15, 2505-2518
CrossRef123
Simona Niederhäusern, Carla Sabia, Patrizia Messi, Elisa Guerrieri, Giuliano Manicardi, Moreno Bondi. (2007) VanA-Type Vancomycin-Resistant Enterococci in Equine and Swine Rectal Swabs and in Human Clinical Samples. Current Microbiology 55:3, 240-246
CrossRef124
Scott D Pope, Andrew M Roecker. (2007) Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Expert Opinion on Pharmacotherapy 8:9, 1245-1261
CrossRef125
Darren Abbanat, Mark Macielag, Karen Bush. 2007. Streptogramins and Oxazolidinones. , 239-266.
CrossRef126
Emilia Cercenado. (2007) Tigecycline: a new antimicrobial agent against multiresistant bacteria. Therapy 4:3, 255-270
CrossRef127
Michael Vercillo, Michael J Patzakis, Paul Holtom, Charalampos G Zalavras. (2007) Linezolid in the Treatment of Implant-related Chronic Osteomyelitis. Clinical Orthopaedics and Related Research PAP,
CrossRef128
Sebastian G.B. Amyes. (2007) Enterococci and streptococci. International Journal of Antimicrobial Agents 29, S43-S52
CrossRef129
F. C. Tenover, R. C. Moellering. (2007) The Rationale for Revising the Clinical and Laboratory Standards Institute Vancomycin Minimal Inhibitory Concentration Interpretive Criteria for Staphylococcus aureus. Clinical Infectious Diseases 44:9, 1208-1215
CrossRef130
A.L. Casey, P.A. Lambert, T.S.J. Elliott. (2007) Staphylococci. International Journal of Antimicrobial Agents 29, S23-S32
CrossRef131
A. Y. Chen, M. J. Zervos, J. A. Vazquez. (2007) Dalbavancin: a novel antimicrobial. International Journal of Clinical Practice 61:5, 853-863
CrossRef132
Michael A. Pfaller, Helio S. Sader, Ronald N. Jones. (2007) Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002–2005). Diagnostic Microbiology and Infectious Disease 57:4, 459-465
CrossRef133
Marianne McCollum, Sonja V. Sorensen, Larry Z. Liu. (2007) A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics 29:3, 469-477
CrossRef134
Tsai-Ling Lauderdale, Yih-Ru Shiau, Hui-Ying Wang, Jui-Fen Lai, I-Wen Huang, Pei-Chen Chen, Hong-Yi Chen, Shiow-Suey Lai, Ya-Fang Liu, Monto Ho. (2007) Effect of banning vancomycin analogue avoparcin on vancomycin-resistant enterococci in chicken farms in Taiwan. Environmental Microbiology 9:3, 819-823
CrossRef135
Duncan Webster, Robert P. Rennie, Cheryl L. Brosnikoff, Linda Chui, Connie Brown. (2007) Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada. Diagnostic Microbiology and Infectious Disease 57:2, 177-181
CrossRef136
R.-P. Vonberg, I.F. Chaberny, A. Kola, F. Mattner, S. Borgmann, M. Dettenkofer, D. Jonas, A.-M. Fahr, I. Klare, G. Werner, K. Weist, C. Wendt, P. Gastmeier. (2007) Prävention und Kontrolle der Ausbreitung von Vancomycin-resistenten Enterokokken. Der Anaesthesist 56:2, 151-157
CrossRef137
Philippa C Matthews, Anthony R Berendt, Benjamin A Lipsky. (2007) Clinical management of diabetic foot infection: diagnostics, therapeutics and the future. Expert Review of Anti-infective Therapy 5:1, 117-127
CrossRef138
Sandy Dubaele, Christophe Martin, Jacqueline Bohn, Patrick Chene. (2007) Biochemical Study of Recombinant PcrA from Staphylococcus aureus for the Development of Screening Assays. Journal of Biochemistry and molecular biology 40:1, 7-14
CrossRef139
Craig A. Hutton, Matthew A. Perugini, Juliet A. Gerrard. (2007) Inhibition of lysine biosynthesis: an evolving antibiotic strategy. Molecular BioSystems 3:7, 458
CrossRef140
Karl A. Hassan, Ronald A. Skurray, Melissa H. Brown. (2007) Active Export Proteins Mediating Drug Resistance in Staphylococci. Journal of Molecular Microbiology and Biotechnology 12:3-4, 180-196
CrossRef141
Jennifer Le, Jay M Lieberman. (2006) Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Children. Pharmacotherapy 26:12, 1758-1770
CrossRef142
B. Wiedemann. (2006) Test results: characterising the antimicrobial activity of daptomycin. Clinical Microbiology and Infection 12:s8, 9-14
CrossRef143
H. S. M. Ammerlaan, M. J. M. Bonten. (2006) Daptomycin: graduation day. Clinical Microbiology and Infection 12:s8, 22-28
CrossRef144
Michael Gebinoga, G. Alexander Groß, Arne Albrecht, Thomas Lübeck, Thomas Henkel, Patrick Hoffmann, Uwe Klemm, Gregor Schlingloff, Thomas Frank, Andreas Schober. (2006) “Syn&Sort”: A Chip-based Tool for Combinatorial Synthesis. QSAR & Combinatorial Science 25:11, 1063-1068
CrossRef145
Liam Evans, John N. Hedger, David Brayford, Michael Stavri, Eileen Smith, Gemma O’Donnell, Alexander I. Gray, Gareth W. Griffith, Simon Gibbons. (2006) An antibacterial hydroxy fusidic acid analogue from Acremonium crotocinigenum. Phytochemistry 67:19, 2110-2114
CrossRef146
L.-X. Zhu, Z.-W. Zhang, C. Wang, H.-W. Yang, Q. Zhang, J. Cheng. (2006) Evaluation of the CLSI cefoxitin 30-ug disk-diffusion method for detecting methicillin resistance in staphylococci. Clinical Microbiology and Infection 12:10, 1039-1042
CrossRef147
Bryndis Sigurdardottir, Jeffery Vande Berg, Jianfang Hu, Josiah Alamu, Louise‐Anne McNutt, Daniel J. Diekema, Loreen A. Herwaldt. (2006) Descriptive Epidemiology and Case‐Control Study of Patients Colonized With Vancomycin‐Resistant Enterococcus and Methicillin‐Resistant Staphylococcus aureus • . Infection Control and Hospital Epidemiology 27:9, 913-919
CrossRef148
Katsunori Yanagihara, Masafumi Seki, Koichi Izumikawa, Yasuhito Higashiyama, Yoshitsugu Miyazaki, Yoichi Hirakata, Kazunori Tomono, Yohei Mizuta, Kazuhiro Tsukamoto, Shigeru Kohno. (2006) Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. International Journal of Antimicrobial Agents 28:3, 212-216
CrossRef149
Darego O. Maclayton, Katie J. Suda, Krista A. Coval, Cynthia B. York, Kevin W. Garey. (2006) Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clinical Therapeutics 28:8, 1208-1216
CrossRef150
Jennifer Tuboku‐Metzger Blakely, Ronda L. Sinkowitz‐Cochran, William R. Jarvis. (2006) Infectious Diseases Physicians' Preferences for Continuing Medical Education on Antimicrobial Resistance and Other General Topics • . Infection Control and Hospital Epidemiology 27:8, 873-875
CrossRef151
Jodi A. Lindsay, Matthew T. G. Holden. (2006) Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Functional & Integrative Genomics 6:3, 186-201
CrossRef152
Louis B. Rice. (2006) Antimicrobial resistance in gram-positive bacteria. American Journal of Infection Control 34:5, S11-S19
CrossRef153
David K. Henderson. (2006) Managing methicillin-resistant staphylococci: A paradigm for preventing nosocomial transmission of resistant organisms. American Journal of Infection Control 34:5, S46-S54
CrossRef154
J. B. Patel, L. A. Jevitt, J. Hageman, L. C. McDonald, F. C. Tenover. (2006) An Association between Reduced Susceptibility to Daptomycin and Reduced Susceptibility to Vancomycin in Staphylococcus aureus. Clinical Infectious Diseases 42:11, 1652-1653
CrossRef155
Fred C. Tenover. (2006) Mechanisms of antimicrobial resistance in bacteria. American Journal of Infection Control 34:5, S3-S10
CrossRef156
P. C. Appelbaum. (2006) MRSA-the tip of the iceberg. Clinical Microbiology and Infection 12:s2, 3-10
CrossRef157
Hossam Al-Tatari, Nahed Abdel-Haq, Pimpanada Chearskul, Basim Asmar. (2006) Antibiotics for treatment of resistant gram-positive coccal infections. The Indian Journal of Pediatrics 73:4, 323-334
CrossRef158
A. Zirakzadeh, R. Patel. (2006) Vancomycin-Resistant Enterococci: Colonization, Infection, Detection, and Treatment. Mayo Clinic Proceedings 81:4, 529-536
CrossRef159
W. V. Kern. (2006) Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. International Journal of Clinical Practice 60:3, 370-378
CrossRef160
D. Rodríguez Pardo, C. Pigrau Serrallach. (2006) Infecciones por estafilococos. Medicine - Programa de Formación Médica Continuada Acreditado 9:50, 3257-3265
CrossRef161
M. J. Rybak. (2006) The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clinical Microbiology and Infection 12:s1, 24-32
CrossRef162
David Hirschwerk, Christine C. Ginocchio, Maureen Bythrow, Susan Condon. (2006) Diminished Susceptibility to Daptomycin Accompanied by Clinical Failure in a Patient With Methicillin‐Resistant Staphylococcus aureus Bacteremia • . Infection Control and Hospital Epidemiology 27:3, 315-317
CrossRef163
P. C. Appelbaum. (2006) The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 12:s1, 16-23
CrossRef164
Zeina A. Kanafani, Vance G. Fowler. (2006) Staphylococcus aureus Infections: New Challenges from an Old Pathogen. Enfermedades Infecciosas y Microbiología Clínica 24:3, 182-193
CrossRef165
Matthew I. Hutchings, Hee-Jeon Hong, Mark J. Buttner. (2006) The vancomycin resistance VanRS two-component signal transduction system of Streptomyces coelicolor. Molecular Microbiology 59:3, 923-935
CrossRef166
L. C. McDonald. (2006) Trends in Antimicrobial Resistance in Health Care-Associated Pathogens and Effect on Treatment. Clinical Infectious Diseases 42:Supplement 2, S65-S71
CrossRef167
D. E. Craven, D. S. Shapiro. (2006) Staphylococcus aureus: Times, They Are A-Changin'. Clinical Infectious Diseases 42:2, 179-180
CrossRef168
Alexander Mellmann, Alexander W. Friedrich, Nicole Rosenkötter, Jörg Rothgänger, Helge Karch, Ralf Reintjes, Dag Harmsen. (2006) Automated DNA Sequence-Based Early Warning System for the Detection of Methicillin-Resistant Staphylococcus aureus Outbreaks. PLoS Medicine 3:3, e33
CrossRef169
Sun Mi Park, Byung Kyu Choe, Chun Soo Kim, Joon Sik Kim, Heung Sik Kim, Nam-Hee Ryoo. (2006) Bacteremia in pediatric cancer patients : A single center study. Korean Journal of Pediatrics 49:8, 882
CrossRef170
D. P. Levine. (2006) Vancomycin: A History. Clinical Infectious Diseases 42:Supplement 1, S5-S12
CrossRef171
R. N. Jones. (2006) Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clinical Infectious Diseases 42:Supplement 1, S13-S24
CrossRef172
Ji-Young Lee, Won Sup Oh, Kwan Soo Ko, Sang Taek Heo, Chi Sook Moon, Hyun Kyun Ki, Sungmin Kiem, Kyong Ran Peck, Jae-Hoon Song. (2006) Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus. Journal of Korean Medical Science 21:2, 188
CrossRef173
S.-H. Kim, W.-B. Park, C.-S. Lee, C.-I. Kang, J.-W. Bang, H.-B. Kim, N.-J. Kim, E.-C. Kim, M. D. Oh, K.-W. Choe. (2006) Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clinical Microbiology and Infection 12:1, 13-21
CrossRef174
Rachel C. Orscheln, Henry R. Shinefield, Joseph W. St. Geme. 2006. Staphylococcal Infections. , 513-543.
CrossRef175
Jennifer M. Streit, Helio S. Sader, Thomas R. Fritsche, Ronald N. Jones. (2005) Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease 53:4, 307-310
CrossRef176
Ali Zirakzadeh, Robin Patel. (2005) Epidemiology and mechanisms of glycopeptide resistance in enterococci. Current Opinion in Infectious Diseases 18:6, 507-512
CrossRef177
Tony Worthington, Tom S.J. Elliott. (2005) Diagnosis of central venous catheter related infection in adult patients. Journal of Infection 51:4, 267-280
CrossRef178
Shigenobu Matsuzaki, Mohammad Rashel, Jumpei Uchiyama, Shingo Sakurai, Takako Ujihara, Masayuki Kuroda, Masahiko Ikeuchi, Toshikazu Tani, Mikiya Fujieda, Hiroshi Wakiguchi, Shosuke Imai. (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. Journal of Infection and Chemotherapy 11:5, 211-219
CrossRef179
Abhijit M Bal, Ian M Gould. (2005) Antibiotic resistance in Staphylococcus aureus and its relevance in therapy. Expert Opinion on Pharmacotherapy 6:13, 2257-2269
CrossRef180
Jon P. Furuno, Eli N. Perencevich, Judith A. Johnson, Marc-Oliver Wright, Jessina C. McGregor, J. Glenn Morris, Sandra M. Strauss, Mary-Claire Roghman, Lucia L. Nemoy, Harold C. Standiford, Joan N. Hebden, Anthony D. Harris. (2005) Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1. Emerging Infectious Diseases 11:10, 1539-1544
CrossRef181
Thomas G. Fraser, Valentina Stosor, Qiong Wang, Anne Allen, Teresa R. Zembower. (2005) Vancomycin and Home Health Care. Emerging Infectious Diseases 11:10, 1558-1564
CrossRef182
Kerstin Herold, Friedrich A. Gollmick, Ingrid Groth, Martin Roth, Klaus-Dieter Menzel, Ute Möllmann, Udo Gräfe, Christian Hertweck. (2005) Cervimycin A-D: A Polyketide Glycoside Complex from a Cave Bacterium Can Defeat Vancomycin Resistance. Chemistry - A European Journal 11:19, 5523-5530
CrossRef183
Alexandra Eisner, Gregor Gorkiewicz, Gebhard Feierl, Eva Leitner, Josef Köfer, Harald H. Kessler, Egon Marth. (2005) Identification of Glycopeptide-resistant enterococci by VITEK 2 system and conventional and real-time polymerase chain reaction. Diagnostic Microbiology and Infectious Disease 53:1, 17-21
CrossRef184
G Perera, R Hay. (2005) A guide to antibiotic resistance in bacterial skin infections. Journal of the European Academy of Dermatology and Venereology 19:5, 531-545
CrossRef185
Stephen H. Zinner. (2005) Overview of Antibiotic Use and Resistance: Setting the Stage for Tigecycline. Clinical Infectious Diseases 41:s5, S289-S292
CrossRef186
PAUL J. FORD, THOMAS G. FRASER, MELLAR P. DAVIS, ERIC KODISH. (2005) ANTI-INFECTIVE THERAPY AT END OF LIFE: ETHICAL DECISION-MAKING IN HOSPICE-ELIGIBLE PATIENTS. Bioethics 19:4, 379-392
CrossRef187
María Victoria Francia. (2005) Enterococcus resistentes a glucopéptidos en Europa: un problema hospitalario creciente. Enfermedades Infecciosas y Microbiología Clínica 23:8, 457-459
CrossRef188
Michael J. Peeters, Juan C. Sarria. (2005) Clinical Characteristics of Linezolid-Resistant Staphylococcus aureus Infections. The American Journal of the Medical Sciences 330:2, 102-104
CrossRef189
E. M. Mascini, M. J. M. Bonten. (2005) Vancomycin-resistant enterococci: consequences for therapy and infection control. Clinical Microbiology and Infection 11:s4, 43-56
CrossRef190
M. H. Wernitz, S. Swidsinski, K. Weist, D. Sohr, W. Witte, K-P. Franke, D. Roloff, H. Ruden, S. K. Veit. (2005) Effectiveness of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA infections. Clinical Microbiology and Infection 11:6, 457-465
CrossRef191
Henrik Hasman, Anette G. Villadsen, Frank M. Aarestrup. (2005) Diversity and Stability of Plasmids from Glycopeptide-Resistant Enterococcus faecium (GRE) Isolated from Pigs in Denmark. Microbial Drug Resistance 11:2, 178-184
CrossRef192
J. M. Eguia, C. Liu, M. Moore, E. M. Wrone, J. Pont, J. L. Gerberding, H. F. Chambers. (2005) Low Colonization Prevalence of Staphylococcus aureus with Reduced Vancomycin Susceptibility among Patients Undergoing Hemodialysis in the San Francisco Bay Area. Clinical Infectious Diseases 40:11, 1617-1624
CrossRef193
F. Menichetti. (2005) Current and emerging serious Gram-positive infections. Clinical Microbiology and Infection 11:s3, 22-28
CrossRef194
P. M. Shah. (2005) The need for new therapeutic agents: what is in the pipeline?. Clinical Microbiology and Infection 11:s3, 36-42
CrossRef195
Jorge García-Lara, Mahmud Masalha, Simon J. Foster. (2005) Staphylococcus aureus: the search for novel targets. Drug Discovery Today 10:9, 643-651
CrossRef196
Tadashi Kitamura, Tetsuro Morota, Noboru Motomura, Minoru Ono, Ko Shibata, Katsuhito Ueno, Yutaka Kotsuka, Shinichi Takamoto. (2005) Management of Infected Grafts and Aneurysms of the Aorta. Annals of Vascular Surgery 19:3, 335-342
CrossRef197
Dora Szabo, Fernanda Silveira, Shigeki Fujitani, David L. Paterson. (2005) Mechanisms of Resistance of Bacteria Causing Ventilator-Associated Pneumonia. Clinics in Chest Medicine 26:1, 75-79
CrossRef198
Fred C. Tenover. (2005) The real vancomycin-resistant Staphylococcus aureus has arrived. Clinical Microbiology Newsletter 27:5, 35-40
CrossRef199
A. C. Gales, H. S. Sader, R. N. Jones. (2005) Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clinical Microbiology and Infection 11:2, 95-100
CrossRef200
Alexander Scherl, Patrice François, Manuela Bento, Jacques M. Deshusses, Yvan Charbonnier, Véronique Converset, Antoine Huyghe, Nadia Walter, Christine Hoogland, Ron D. Appel, Jean-Charles Sanchez, Catherine G. Zimmermann-Ivol, Garry L. Corthals, Denis F. Hochstrasser, Jacques Schrenzel. (2005) Correlation of proteomic and transcriptomic profiles of Staphylococcus aureus during the post-exponential phase of growth. Journal of Microbiological Methods 60:2, 247-257
CrossRef201
Michael N Alekshun. (2005) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: an update on new antibiotics, novel non-antibacterial treatment modalities and critical issues in antibiotic resistance. Expert Opinion on Investigational Drugs 14:1, 93-99
CrossRef202
S. J. Berman, E. W. Johnson, C. Nakatsu, M. Alkan, R. Chen, J. LeDuc. (2004) Burden of Infection in Patients with End-Stage Renal Disease Requiring Long-Term Dialysis. Clinical Infectious Diseases 39:12, 1747-1753
CrossRef203
Joseph M. Patti. (2004) A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22, S39-S43
CrossRef204
William R. Jarvis. (2004) The State of the Science of health care epidemiology, infection control, and patient safety, 2004. American Journal of Infection Control 32:8, 496-503
CrossRef205
Henrik Stender. 2004. PNA–FISH—Applications for Rapid Diagnosis of Bloodstream Infections. , 1031-1035.
CrossRef206
S. Niederhausern, C. Sabia, P. Messi, E. Guerrieri, G. Manicardi, M. Bondi. (2004) Glycopeptide-resistance transferability from vancomycin-resistant enterococci of human and animal source to Listeria spp.. Letters in Applied Microbiology 39:6, 483-489
CrossRef207
Richard H. Drew. (2004) Key References in Infectious Diseases Pharmacotherapy. Pharmacotherapy 24:11, 1586-1593
CrossRef208
Kerry L LaPlante, Michael J Rybak. (2004) Daptomycin – a novel antibiotic against Gram-positive pathogens. Expert Opinion on Pharmacotherapy 5:11, 2321-2331
CrossRef209
Marc J. M Bonten. (2004) Prevention of infection in the intensive care unit. Current Opinion in Critical Care 10:5, 364-368
CrossRef210
Kerry L. LaPlante, Michael J. Rybak. (2004) Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagnostic Microbiology and Infectious Disease 50:2, 125-130
CrossRef211
W. Witte. (2004) Glycopeptide resistant Staphylococcus. Journal of Veterinary Medicine Series B 51:8-9, 370-373
CrossRef212
E. Lindberg, I. Adlerberth, A. E. Wold. (2004) Antibiotic resistance in Staphylococcus aureus colonising the intestines of Swedish infants. Clinical Microbiology and Infection 10:10, 890-894
CrossRef213
Maria Joyce, Christopher W Woods. (2004) Antibacterial susceptibility testing in the clinical laboratory. Infectious Disease Clinics of North America 18:3, 401-434
CrossRef214
Marc J. Struelens, Olivier Denis, Hector Rodriguez-Villalobos. (2004) Microbiology of nosocomial infections: progress and challenges. Microbes and Infection 6:11, 1043-1048
CrossRef215
James S. Tan. (2004) Foot Infections in diabetic patients. Current Infectious Disease Reports 6:5, 377-379
CrossRef216
Stefanie Koch, Markus Hufnagel, Johannes Huebner. (2004) Treatment and prevention of enterococcal infections – alternative and experimental approaches. Expert Opinion on Biological Therapy 4:9, 1519-1531
CrossRef217
Tammy S Lundstrom, Jack D Sobel. (2004) Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infectious Disease Clinics of North America 18:3, 651-668
CrossRef218
Barry I Eisenstein. (2004) Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opinion on Investigational Drugs 13:9, 1159-1169
CrossRef219
S. E. Cosgrove, K. C. Carroll, T. M. Perl. (2004) Staphylococcus aureus with Reduced Susceptibility to Vancomycin. Clinical Infectious Diseases 39:4, 539-545
CrossRef220
Jodi A. Lindsay, Matthew T.G. Holden. (2004) Staphylococcus aureus: superbug, super genome?. Trends in Microbiology 12:8, 378-385
CrossRef221
Barry M Farr. (2004) Prevention and control of methicillin-resistant Staphylococcus aureus infections. Current Opinion in Infectious Diseases 17:4, 317-322
CrossRef222
Keiichi Hiramatsu, Longzhu Cui, Kyoko Kuwahara-Arai. (2004) Has vancomycin-resistant Staphylococcus aureus started going it alone?. The Lancet 364:9434, 565-566
CrossRef223
J. R. McDonald, J. J. Engemann, K. S. Kaye, D. J. Sexton. (2004) Co‐Infection or Co‐Colonization With Vancomycin‐Resistant Enterococci and Methicillin‐Resistant Staphylococcus aureus in a Network of Community Hospitals • . Infection Control and Hospital Epidemiology 25:8, 622-622
CrossRef224
Jean Carlet, Adel Ben Ali, Annie Chalfine. (2004) Epidemiology and control of antibiotic resistance in the intensive care unit. Current Opinion in Infectious Diseases 17:4, 309-316
CrossRef225
E. S. D. Ashley, D. N. Carroll, J. J. Engemann, A. D. Harris, V. G. Fowler, D. J. Sexton, K. S. Kaye. (2004) Risk Factors for Postoperative Mediastinitis Due to Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases 38:11, 1555-1560
CrossRef226
Joseph M Patti. (2004) Immunotherapeutics for nosocomial infections. Expert Opinion on Investigational Drugs 13:6, 673-679
CrossRef227
Shu-Wei Yang, Ling Xu, Ronald Mierzwa, Ling He, Joseph Terracciano, Mahesh Patel, Vincent Gullo, Todd Black, Wenjun Zhao, Tze-Ming Chan, Min Chu. (2004) Two novel antibiotics, Sch 419558 and Sch 419559, produced by Pseudomonas fluorescens: effect on activity by overexpression of RpoE. Bioorganic & Medicinal Chemistry 12:12, 3333-3338
CrossRef228
Louis Bernard, Pierre Vaudaux, Peter Rohner, Elzbieta Huggler, Mathieu Armanet, Didier Pittet, Daniel P. Lew, Jacques Schrenzel. (2004) Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains. Journal of Microbiological Methods 57:2, 231-239
CrossRef229
Hee-Jeon Hong, Matthew I. Hutchings, John M. Neu, Gerard D. Wright, Mark S. B. Paget, Mark J. Buttner. (2004) Characterization of an inducible vancomycin resistance system in Streptomyces coelicolor reveals a novel gene (vanK) required for drug resistance. Molecular Microbiology 52:4, 1107-1121
CrossRef230
Cynthia J. Whitener, Sarah Y. Park, Fred A. Browne, Leslie J. Parent, Kathleen Julian, Bülent Bozdogan, Peter C. Appelbaum, Jasmine Chaitram, Linda M. Weigel, John Jernigan, Linda K. McDougal, Fred C. Tenover, Scott K. Fridkin. (2004) Vancomycin‐Resistant Staphylococcus aureus in the Absence of Vancomycin Exposure. Clinical Infectious Diseases 38:8, 1049-1055
CrossRef231
Christopher F. Carpenter, Henry F. Chambers. (2004) Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens. Clinical Infectious Diseases 38:7, 994-1000
CrossRef232
Barry M Farr. (2004) The state of the science. American Journal of Infection Control 32:2, 106-113
CrossRef233
Rebecca H. Sunenshine, Laura A. Liedtke, Daniel B. Jernigan, Larry J. Strausbaugh, . (2004) Role of Infectious Diseases Consultants in Management of Antimicrobial Use in Hospitals. Clinical Infectious Diseases 38:7, 934-938
CrossRef234
John E. McGowan, Fred C. Tenover. (2004) Opinion: Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists. Nature Reviews Microbiology 2:3, 251-258
CrossRef235
David K. Warren, Anand Nitin, Cheri Hill, Victoria J. Fraser, Marin H. Kollef. (2004) Occurrence of Co‐Colonization or Co‐Infection With Vancomycin‐Resistant Enterococci and Methicillin‐Resistant Staphylococcus aureus in a Medical Intensive Care Unit • . Infection Control and Hospital Epidemiology 25:2, 99-104
CrossRef236
Allison McGeer. (2004) News in Antimicrobial Resistance: Documenting the Progress of Pathogens • . Infection Control and Hospital Epidemiology 25:2, 97-98
CrossRef237
Anita Bhalla, Nicole J. Pultz, Delores M. Gries, Amy J. Ray, Elizabeth C. Eckstein, David C. Aron, Curtis J. Donskey. (2004) Acquisition of Nosocomial Pathogens on Hands After Contact With Environmental Surfaces Near Hospitalized Patients • . Infection Control and Hospital Epidemiology 25:2, 164-167
CrossRef238
Marc‐Oliver Wright, Joan N. Hebden, Anthony D. Harris, Carl B. Shanholtz, Harold C. Standiford, Jon P. Furuno, Eli N. Perencevich. (2004) Aggressive Control Measures for Resistant Acinetobacter baumannii and the Impact on Acquisition of Methicillin‐Resistant Staphylococcus aureus and Vancomycin‐Resistant Enterococcus in a Medical Intensive Care Unit • . Infection Control and Hospital Epidemiology 25:2, 167-168
CrossRef239
Stefanie Koch, Markus Hufnagel, Christian Theilacker, Johannes Huebner. (2004) Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine 22:7, 822-830
CrossRef240
Jennifer M Streit, Thomas R Fritsche, Helio S Sader, Ronald N Jones. (2004) Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagnostic Microbiology and Infectious Disease 48:2, 137-143
CrossRef241
Mark Loeb, Allison McGeer, Andrew Simor, Stephen D. Walter, Suzanne Bradley, Donald E. Low, Lorraine Moss. (2004) Facility‐Level Correlates of Antimicrobial Use in Nursing Homes • . Infection Control and Hospital Epidemiology 25:2, 173-176
CrossRef242
Andrea Marra. (2004) Can virulence factors be viable antibacterial targets?. Expert Review of Anti-infective Therapy 2:1, 61-72
CrossRef243
Rosa V. Rosario‐Rosado, Antonio A. Rene, Bobby Jones. (2004) Descriptive Analysis of Patients With Community‐Onset and Hospital‐Onset Methicillin‐Resistant Staphylococcus aureus Infections • . Infection Control and Hospital Epidemiology 25:2, 171-173
CrossRef244
Salih Cesur, Fugen Eokca. (2004) Nasal Carriage of Methicillin‐Resistant Staphylococcus aureus Among Hospital Staff and Outpatients • . Infection Control and Hospital Epidemiology 25:2, 169-171
CrossRef245
Didier Lepelletier, Stephanie Perron, Helene Huguenin, Monique Picard, Pascale Bemer, Jocelyne Caillon, Marie‐Emmanuelle Juvin, Henri Bernard Drugeon. (2004) Which Strategies Follow From the Surveillance of Multidrug‐Resistant Bacteria to Strengthen the Control of Their Spread? A French Experience • . Infection Control and Hospital Epidemiology 25:2, 162-164
CrossRef246
Kerry L. Tedesco, Michael J. Rybak. (2004) Daptomycin. Pharmacotherapy 24:1, 41-57
CrossRef247
Fran??oise Van Bambeke, Yves Van Laethem, Patrice Courvalin, Paul M Tulkens. (2004) Glycopeptide Antibiotics. Drugs 64:9, 913-936
CrossRef248
Ellie Hershberger, Susan Donabedian, Konstantinos Konstantinou, Marcus J. Zervos. (2004) Quinupristin‐Dalfopristin Resistance in Gram‐Positive Bacteria: Mechanism of Resistance and Epidemiology. Clinical Infectious Diseases 38:1, 92-98
CrossRef249
Caroline Fenton, Gillian M Keating, Monique P Curran. (2004) Daptomycin. Drugs 64:4, 445-455
CrossRef250
Jason Hill, James Siedlecki, Ian Parr, Michael Morytko, Xiang Yu, Yanzhi Zhang, Jared Silverman, Nicole Controneo, Valerie Laganas, Tongchuan Li, Jan-Ji Lai, Dennis Keith, George Shimer, John Finn. (2003) Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin. Bioorganic & Medicinal Chemistry Letters 13:23, 4187-4191
CrossRef251
James Siedlecki, Jason Hill, Ian Parr, Xiang Yu, Michael Morytko, Yanzhi Zhang, Jared Silverman, Nicole Controneo, Valerie Laganas, Tongchuan Li, Jianshi Li, Dennis Keith, George Shimer, John Finn. (2003) Array synthesis of novel lipodepsipeptide. Bioorganic & Medicinal Chemistry Letters 13:23, 4245-4249
CrossRef252
J.Kevin Judice, John L. Pace. (2003) Semi-synthetic glycopeptide antibacterials. Bioorganic & Medicinal Chemistry Letters 13:23, 4165-4168
CrossRef253
Marianne McCollum, David C. Rhew, Stephen Parodi. (2003) Cost analysis of switching from IV vancomycin to PO linezolid for the management of methicillin-resistant Staphylococcus species. Clinical Therapeutics 25:12, 3173-3189
CrossRef254
Marc J.M. Bonten. (2003) Prevention of hospital-acquired pneumonia:. Infectious Disease Clinics of North America 17:4, 773-784
CrossRef255
JAY M. LIEBERMAN. (2003) Appropriate antibiotic use and why it is important: the challenges of bacterial resistance. The Pediatric Infectious Disease Journal 22:12, 1143-1151
CrossRef256
Laura Troidle, Nancy Gorban-Brennan, Alan Kliger, Fredric O. Finkelstein. (2003) RENAL RESEARCH INSTITUTE SYMPOSIUM: Continuous Peritoneal Dialysis-Associated Peritonitis: A Review and Current Concepts. Seminars in Dialysis 16:6, 428-437
CrossRef257
Nina M. Clark, Ellie Hershberger, Marcus J. Zervosc, Joseph P. Lynch. (2003) Antimicrobial resistance among gram-positive organisms in the intensive care unit. Current Opinion in Critical Care 9:5, 403-412
CrossRef258
A. J. Ray, N. J. Pultz, A. Bhalla, D. C. Aron, C. J. Donskey. (2003) Coexistence of Vancomycin-Resistant Enterococci and Staphylococcus aureus in the Intestinal Tracts of Hospitalized Patients. Clinical Infectious Diseases 37:7, 875-881
CrossRef259
Henrik Stender. (2003) PNA FISH: an intelligent stain for rapid diagnosis of infectious diseases. Expert Review of Molecular Diagnostics 3:5, 649-655
CrossRef260
Marc J. M. Bonten, Hajo Grundmann. (2003) Selective digestive decontamination and antibiotic resistance: A balancing act *. Critical Care Medicine 31:8, 2239-2240
CrossRef261
Battouli Said‐Salim, Barun Mathema, Barry N. Kreiswirth. (2003) Community‐Acquired Methicillin‐Resistant Staphylococcus aureus : An Emerging Pathogen • . Infection Control and Hospital Epidemiology 24:6, 451-455
CrossRef262
M. Edmond. (2003) Cost‐effectiveness of perirectal surveillance cultures for controlling vancomycin‐resistant Enterococcus. Infection Control and Hospital Epidemiology 24:5, 309-302
CrossRef263
J. M. Munoz, A. E. Macias. (2003) Nosocomial outbreak of Serratia marcescens in a neonatal intensive care unit. Infection Control and Hospital Epidemiology 24:5, 312-313
CrossRef
